Tesamorelin vs P21
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesFat Loss & Metabolic
TesamorelinCognitive EnhancementAnti-Aging & Longevity
P21- Summary
- Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
- P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
- Half-Life
- ~26 minutes
- Not well characterized; likely short, but neurogenic effects persist long after administration
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 2 mg
- 100–500 mcg
- Frequency
- Once daily
- Once daily
- Key Benefits
- FDA-approved for visceral fat reduction in HIV lipodystrophy
- Significant reduction in trunk/visceral fat (average 15–20% in trials)
- Improved triglyceride and lipid profiles
- Potential cognitive benefits and memory improvement
- Preserves lean mass while reducing fat
- Natural pulsatile GH stimulation
- Promotes hippocampal neurogenesis
- Enhances spatial memory and learning
- Increases BDNF expression
- Reduces amyloid-beta plaque formation (animal models)
- Anti-tau pathology potential
- Cognitive enhancement without stimulant effects
- Potential therapeutic for Alzheimer's and cognitive aging
- Side Effects
- Injection site reactions (redness, irritation)
- Arthralgia and joint pain
- Peripheral edema
- Carpal tunnel syndrome
- +2 more
- Generally well tolerated in animal studies
- Limited human clinical data
- Injection site reactions
- Potential mild fatigue at initiation
- Stacks With
- —
- —